SCHEMBL7987990

SCHEMBL7987990

O=C1c2ccccc2C(O)(c2ccc(F)cc2)N1Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2455265 1.00 MDM2 (1.00) MDM2
SCHEMBL1822510 0.91 MDM2 (1.00) MDM2
SCHEMBL7976509 0.91 MDM2 (1.00) MDM2
SCHEMBL1820534 0.90 MDM2 (1.00) MDM2
SCHEMBL20100160 0.86 MDM2 (0.75) MDM2
SCHEMBL1823371 0.85 MDM2 (0.88) MDM2
SCHEMBL21539978 0.85 MDM2 (0.74) MDM2
SCHEMBL2458225 0.84 MDM2 (1.00) MDM2
SCHEMBL2458483 0.84 MDM2 (1.00) MDM2
SCHEMBL7990779 0.84 MDM2 (1.00) MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2960233-B1 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECH LTD (GB) 2019-10-30 EP disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-9358222-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-07 US disclosed
US-9358222-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-07 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
WO-2009156735-A2 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194486-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885
US-20110224274-A1 New Therapeutic Agents TP53, MDM2, TP53BP1 MDM2 2/4885
US-20180118684-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885
US-20160355478-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 MDM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.